These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Author: Tanaka M.
    Journal: Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741.
    Abstract:
    The effect of human recombinant GM-CSF (rGM-CSF) on the metabolism of high dose ara-C was determined in bone marrow mononuclear cells (BMMCs) from eight normal volunteers and from seven patients with acute myelogenous leukemia (AML). We incubated the cells with rGM-CSF alone, ara-C alone, or a combination of the two drugs. Treatment with rGM-CSF for 16 h increased the percentage of cells in S-phase both in normal BMMCs and leukemic marrow cells. The treatment with rGM-CSF alone produced an approximately two-fold increase in the intracellular dCTP pools in normal BMMCs, but this increment was not observed in leukemic marrow cells. Simultaneous exposure to rGM-CSF in combination with ara-C increased cytosine arabinoside triphosphate (ara-CTP) pools in leukemic blasts. In contrast, this treatment decreased ara-CTP pools in normal BMMCs. Moreover, when the cells were preincubated with rGM-CSF for 16 h prior to the exposure to ara-C, leukemic blasts achieved a 7-fold higher ara-CTP/dCTP ratio as compared with normal marrow cells. Treatment of the cells with rGM-CSF, either simultaneously or sequentially, resulted in significantly greater amounts of ara-C incorporation into DNA in leukemic marrow cells than normal counterparts. The higher accumulation of ara-CTP and subsequent increased incorporation of ara-C into DNA in leukemic cells treated with rGM-CSF lead to the enhanced ara-C-mediated inhibition of DNA synthesis as compared with normal BMMCs. The selective accumulation of ara-CTP in leukemic vs normal cells have implications for the efficacy of the treatment of AML patients with high dose ara-C and rGM-CSF.
    [Abstract] [Full Text] [Related] [New Search]